Foresite Capital Management Iv, LLC Aerie Pharmaceuticals Inc Transaction History

Foresite Capital Management Iv, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$12.0 - $16.13 $2.73 Million - $3.67 Million	-227,717 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$11.84 - $25.52 $15.1 Million - $32.5 Million	-1,273,683 Reduced 84.83%	227,717 $3.07 Million
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $1.78 Million - $2.52 Million	100,500 Added 7.17%	1,501,400 $36.3 Million
Q3 2019 Nov 13, 2019	BUY	$18.41 - $28.0 $14.7 Million - $22.4 Million	800,900 Added 133.48%	1,400,900 $26.9 Million
Q2 2019 Aug 13, 2019	BUY	$28.97 - $48.21 $11.2 Million - $18.7 Million	388,177 Added 183.26%	600,000 $17.7 Million
Q1 2019 May 14, 2019	SELL	$36.32 - $49.25 $1.82 Million - $2.46 Million	-50,000 Reduced 19.1%	211,823 $10.1 Million
Q4 2018 Feb 13, 2019	BUY	$33.0 - $60.04 $8.64 Million - $15.7 Million	261,823 New	261,823 $9.45 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iv, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iv, LLC with notifications on news.